background after treatment cessation, a high prevalence of relapse was reported in chronic hepatitis b (chb) patients in china, especially in nucleot(s)ide analogues (nucs)-experienced patients. re-treatment for these patients remains unsolved. objectives this study aims to evaluate the efficacy of pegylated interferon in hbeag positive patients with exposure to antiviral therapy. patients and ...

s+%26+Virtual+Meeting/Abstracts?&vmview;=abst_detail_view&confID;=47&abstractID;=33295; cited March 30, 2009]4. Kirkwood JM, Manola J, Ibrahim J, Sondak V, Ernstoff MS, Rao U on behalf of the Eastern Cooperative Oncology Group. A pooled analysis of Eastern Cooperative Oncology Group and Intergroup trials of adjuvant high-dose interferon for melanoma. Clin Cancer Res 2004;10:1670–7. 5. Kilbridg...

Adjuvant therapy for patients with melanoma using interferon remains controversial despite numerous randomized clinical trials. There can be no doubt that interferon works—that is, it has biologic activity sufficient to alter the natural history of resected melanoma. Multiple randomized trials have demonstrated that adjuvant interferon prolongs recurrence free survival compared with observation...

BACKGROUND Recent genome-wide association studies revealed the rs12979860 single nucleotide polymorphism (SNP) of the IL28B gene (CC genotype) to be the strongest pre-therapeutic predictor of therapy response to interferon alpha in patients with chronic hepatitis C infection. The favorable CC genotype is associated with significantly higher rates of sustained virologic response. No data exist o...

Clinical trials for chronic hepatitis B (HBV) infection in children have shown usefulness of interferon alpha 2b (IFN-alpha) in eliminating HBV replication and in improving liver histology. Although it is not the ultimate goal of the interferon treatment for chronic HBV infection, it has been suggested in adults that HBsAg clearance decreases the likelihood of development of hepatocellular carc...

OBJECTIVE To investigate the long-term efficacy and safety of low-dose and dose-escalating therapy of interferon alfa-2a in the treatment of Behçet uveitis. METHODS This study included 37 patients with refractory Behçet panuveitis unresponsive to conventional immunosuppressive therapy. Induction interferon alfa-2a therapy was given as a daily dose of 3.0 million IU (MIU) subcutaneously for 14...

Intravenous injection of polyinosinic acid/polycytidylic acid [(poly rI).(poly rC)] offered significant protection against intranasal challenge of young mice with vesicular stomatitis virus (VSV). Optimal protection was obtained when a single dose was administered 2 hr before virus challenge, but repeated doses were effective when started as late as 3 days after virus challenge. The therapeutic...

A series of anthraquinones with amino substituents at the 1,5 positions were found to induce interferon in mice. A prototype compound, 1,5-bis[(3-morpholinopropyl)amino]-anthraquinone (Ia), was an effective antiviral agent when administered either orally or parenterally. Peak interferon titers were found 12 to 24 h after drug treatment. The minimum oral dose of Ia required to induce serum inter...